FUMARI, INC. – Trademark Portfolio
Entity Type: 03
FUMARI, INC. holds 67 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 34 (Smokers Articles) — 56 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 5 Nice Classification classes. Currently, 28 trademarks are registered and 5 are pending. Notable registered marks include RGB, WGB, FUMARI, LEMON MINT, and SHAKA GUAVA. The owner is based in SAN DIEGO, CA.
675 GATEWAY CENTER DRIVE, STE A
SAN DIEGO, CA 92102
Showing of trademarks Trademarks
Trademark Classifications
FUMARI, INC.'s trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Education; providing of training; entertainment; sporting and cultural activities
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does FUMARI, INC. have?
FUMARI, INC. has 67 U.S. trademarks filed with the USPTO. Of these, 28 registered, 5 pending, 24 abandoned, 10 cancelled.
What trademark classes does FUMARI, INC. file in?
FUMARI, INC. files trademarks across 5 Nice Classification classes. The most active classes are Class 34 (Smokers Articles), Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 35 (Advertising & Business), Class 43 (Hotels & Restaurants). Class 34 covers tobacco; smokers articles; matches.
What are FUMARI, INC.'s most well-known trademarks?
FUMARI, INC.'s registered trademark portfolio includes well-known marks such as RGB, WGB, FUMARI, LEMON MINT, and SHAKA GUAVA. These are among 28 currently registered trademarks in the portfolio.
What is FUMARI, INC.'s trademark registration success rate?
FUMARI, INC. has a 45% trademark registration rate, with 28 out of 62 resolved applications resulting in successful registration. Currently, 5 applications are pending review.